1 of 9

SEQ ID NO:1:

GGCATATTAGCTTGGGTTACTGTGAATTTTCTGACAGGTCAGCTGCATGGCCACAGA CAGGAGACTGTGGGGACCTTGGACCTAGGGGGAGCCTCCACCCAAATCACGTTCCT GCCCCAGTTTGAGAAAACTCTGGAACAACTCCTAGGGGCTACCTCACTTCCTTTGA GATGTTTAACAGCACTTATAAGCTCTATACACATAGTTACCTGGGATTTGGATTGAA AGCTGCAAGACTAGCAACCCTGGGAGCCCTGGAGACAGAAGGGACTGATGGGCACA'

SEQ ID NO:2:

GCGGGCTGCCGCGCAAGGGTGGCGCGCGCGCGTTTTCCTTGTTCCTGGTCAACAAAG AAATGTGGAGTGTCTTGGCTGAATCCTCATACAGACAAGATCATTATGGTGCTGTTA GGTTGAAAAGTGATATAAAGGAACCAAGGAGAAAATTCAGAAGGAAAGAA AAATTGCCTCTGCAGGTGTGCGAGCAGGATTGCTTCTGCAACAAAGCCTCCACCCA GCCACATCTTGGGAAAAGAATGGCCACTTCTTGGGGCACAGTCTTTTTCATGCTGGT GGTATCCTGTGTTTGCAGCGCTGTCTCCCACAGGAACCAGCAGACTTGGTTTGAGGG TATCTTCCTGTCTTCCATGTGCCCCATCAATGTCAGCGCCAGCACCTTGTATGGAATT ATGTTTGATGCAGGGAGCACTGGAACTCGAATTCATGTTTACACCTTTGTGCAGAAA ATGCCAGGACAGCTTCCAATTCTAGAAGGGGAAGTTTTTGATTCTGTGAAGCCAGGA CTTTCTGCTTTTGTAGATCAACCTAAGCAGGGTGCTGAGACCGTTCAAGGGCTCTTA GAGGTGGCCAAAGACTCAATCCCCCGAAGTCACTGGAAAAAGACCCCAGTGGTCCT AAAGGCAACAGCAGGACTACGCTTACTGCCAGAACACAAAGCCAAGGCTCTGCTCT TTGAGGTAAAGGAGTCTTCAGGAAGTCACCTTTCCTGGTACCAAAGGGCAGTGTTA GCATCATGGATGGATCCGACGAAGGCATATTAGCTTGGGTTACTGTGAATTTTCTGA CAGGTCAGCTGCATGGCCACAGACAGGAGACTGTGGGGGACCTTGGACCTAGGGGGA GCCTCCACCCAAATCACGTTCCTGCCCCAGTTTGAGAAAACTCTGGAACAACTCCT AGGGGCTACCTCACTTCCTTTGAGATGTTTAACAGCACTTATAAGCTCTATACACAT AGTTACCTGGGATTTGGATTGAAAGCTGCAAGACTAGCAACCCTGGGAGCCCTGGA GACAGAAGGGACTGATGGGCACACTTTCCGGAGTGCCTGTTTACCGAGATGGTTGG AAGCAGAGTGGATCTTTGGGGGGTGTGAAATACCAGTATGGTGGCAACCAAGAAGGG GAGGTGGGCTTTGAGCCCTATGCCGAAGTGCTGAGGGTGGTACGAGGAAAACT TCACCAGCCAGAGGGTCCAGAGAGGTTCCTTCTATGCTTTCTCTTACTATTATGA CCGAGCTGTTGACACAGACATGATTGATTATGAAAAGGGGGGGTATTTTAAAAGTTGA AGATTTTGAAAGAAAGCCAGGGAAGTGTGTGATAACTTGGAAAACTTCACCTCAG GCAGTCCTTTCCTGTGCATGGATCTCAGCTACATCACAGCCCTGTTAAAGGATGGCT ACGGGCTGGGCCTTGGGGCCACCTTTCACCTGTTGCAGTCTCTGGGCATCTCCCAT TGAGGCCACGTACTTCCTTGGAGACCTGCATTTGCCAACACCTTTTTAAGGGGAGGA GAGAGCACTTAGTTTCTGAACTAGTCTGGGGACATCCTGGACTTGAGCCTAGAGATT WRGTTAATTAASCGGCCGAGCTTATCCTTWATRAGGTAATTTACTTGCMTGGCCGCG TTTACACGTCGTGATGGNAAACCTGCGTCCCAACTAACGCTTGASAMATCCCCTTCG CAGCTGCGATACCAAAAGCCGACGACGCCTTCCACAGTGCCA

Title: Methods and Materials Relating to Novel
CD39-Like Polypeptides
Figure 2

SEQ ID NO:3:

MATSWGTVFFMLVVSCVCSAVSHRNQQTWFEGIFLSSMCPINVSASTLYGIMFDAGSTG TRIHVYTFVQKMPGQLPILEGEVFDSVKPGLSAFVDQPKQGAETVQGLLEVAKDSIPRSH WKKTPVVLKATAGLRLLPEHKAKALLFEVKEIFRKSPFLVPKGSVSIMDGSDEGILAWV TVNFLTGQLHGHRQETVGTLDLGGASTQITFLPQFEKTLEQTPRGYLTSFEMFNSTYKLY THSYLGFGLKAARLATLGALETEGTDGHTFRSACLPRWLEAEWIFGGVKYQYGGNQEG EVGFEPCYAEVLRVVRGKLHQPEEVQRGSFYAFSYYYDRAVDTDMIDYEKGGILKVED FERKAREVCDNLENFTSGSPFLCMDLSYITALLKDGFGFADSTVLQLTKKVNNIETGWA LGATFHLLQSLGISH

Figure 2

CD39Human.seq M	€ :
CO39Human, seq CONK ALPENNKYGIVLDAGSSHTSLVIVEWERSEREND TO 245 prot USS MCPINVSASTELYGIWEDAGSTOTA IHWYTEVÇKMEGÇT	;
CD39Hamen. seq	:: ::
CD39H:man.seq WIPRSCHOETPVYLGATAGMRLLEMESEELADRULDVVER 15 246 prot SIPRSHWKKTPVIVLUKIATAGILIRLL PLEHKIAKALLEFEVIKE 15	
CD39Hamen.seq S L S N Y P F D F O G A R I I T G O E E G A Y G W I T I N Y L L G K F S O K IS 246 prot I F R K S P F L V P K G S V S I M D G S D E G I L A W V T V N F L T G Q L 18	92 57
CD39Human, seq TEWFSIVPYETNNQEFFGALDLGGASTQVTFVPQ-NQTIEJ 23 246 prot	
CD39Human.seq S P D N A L O F R L Y G K D Y N V Y T H S F L C Y G K D O A L W C K L A K D 26 246 prot Q T P R G Y L T S F E M F N S T Y K L Y T H S Y L G F G L K A A R L A T L 25	:59 :55
CD39HLTEN.SEQ TOVASNEILRDPCFHPGYKKVVNVSDLYKTPCTKR-FEMT 30 246 prot GALELTEGTDGHTFRISACLPRWLEAE 28	:CS : S O
CD39Human.seq [LPF00]EIOGIGNYOOCHOSILELFNTSYCPYSO] 346 prot WIEGGVKYQYGGNQEGEVGFEPCYAEWURVVRGK 33	
CD39Humanuseq C A F N G I F L P P L O G D F G A F S A F Y F V M K F L N L T S E K V S O E 36 246 prot L H Q P E E V Q R G S F Y A F S Y Y Y D R A V D T D M L D Y E 36	80 45
CD39Human.seg KVTEM-MKKFCACPWEEIKTSYAGVKEKYUSEYCFSGT 4: 246 prot KGGILKVEDEERKAREVCDNLEMFTSGSP-FUCMDUS 38	117 181
CD39Human.seg YILSLLLOGYHFTADSWEHIHFIGKIOGSDAGWTLGYMLN 4 246 prot YITALLK DGFGFADST VLQLTKKVNNIETGWALGATFH 4	157 119
CD37.CRC1.Seq 16 1 W 13 1 F F. E. C. F. E. S. F. E. S. F. E. S. F. E. S. F. F. E. S. F. F. E. S. F. F. E.	197 128
	510 129

Figure 3

Fitle: Methods and Materials Relating to Novel CD39-Like Polypeptides

~ ~ ~ ~ ~ · · ·	· o.)popc.
Figure 4	

<pre>1 MATSWGTVFFMLVVSCVCSAVSHRNQQTWFEGIFL3 1 MATSWGAVF-MLIIACVGSTVFYREQCTWFEGVFLS</pre>	S M C P 146 prot <u>S M C P</u> mun htpase
4 INVSASTLYGIMEDAGSTGTRIHVYTEVQK <u>MP</u> GQUE	1 1 E G 046 prot
4 INVSAGTEYGIMEDAGSTGTRIHVYTEVCKTAGOLE	F 1 E G mur nopese
EL EVEDSVKPGLSAFVDQPKQGAETVQGLLEVAKDSIP 80 EIFDSVKPGLSAFVDQPKQGAETVQELLEVAKDSIP	R S H W Dur nipase
121 KKTPVVLKATAGLRELPENKAKIALEIFIEVIKIEI FIRKISP 120 ERITPVVLKATAGLRELPENKAQALELEVEEI FKNSP	FLV P Dur htpese
161 KIG S V S I M D G S D E G I L A W V T V N F L T G Q L H G H R Q E T V G	7 1 0 1 246 prot
SO D G S V S I M D G S Y L E G I L A W V T V N F L T G Q L H G R IG Q E T V G	7 1 0 1 mur napese
201 GGASTQITFLPQFEKTLEQTPRGYLTSFEMFNST <u>Y</u> K	L Y T H 246 prot
200 GGASTOITFLPOFEKTLEOTPRGYLTSFEMFNSTFK	L Y T H mur ntpase
241 SYLGFGLKAARLATLGALETEGTDGHTFRSACLPRW	L E A E 246 prot
240 SYLGFGLKAARLATLGALEAKGTDGHTFRSACLPRW	L E A E mur napese
281 W I F G G V K Y Q Y G G N Q E G E V G F E P C Y A E V L R V V R G K L H 280 W I F G G V K Y O Y G G N O E G E M G F E P C Y A E V L R V V O G K L H	Q P E E 246 prot Q P E E mur napese
321 VORGSFYAFSYYYDRAADTHLIDYEKGGILKVEDFE	RKAR 246 prot
320 VRGSAFYAFSYYYDRAADTHLIDYEKGGVLKVEDFE	RKAR mur nupase
361 EVCDNLENFTSGSPFLCMDLSYITALLKDGFGFADS	TVLIQ 24 Trot
360 EVCDNLGSFSSGSPFLCMDLTYITALLKDGLGFAER	HPLT m: Tpase
401 LTKKVN <mark>NIETGW-ALGAMFHULOSUGIS</mark>	H 246 prot
400 -AHKE <u>SEQHRDWLGUGGHUSPAPVSGHH</u> QURPSSTS	EACI mur ntpese
426	246 prot
439 <u>SEPVESOEGVDSETESDUSGKAWPETR</u>	mur ncpase

Figure 4

Figure 5

Apyrase Conserved Regions in CD39-L4




FIG. 5


Figure 6

Nucleotide sequence of the CD39-L4 mutant ACRIII (SEQ ID NO:6). The nucleotide changes have been highlighted. The G to A and A to C changes at positions 502 and 503 produce a Thr, the T to C, C to A and C to A changes at positions 508-510 result in a Gln and the A to C changed at position 525 result in a Phe.

ATGGCCACTTCTTGGGGCACAGTCTTTTTCATGCTGGTGTATCCTGTGTTTTGCAGCGCTGTCT CCCACAGGAACCAGCAGACTTGGTTTGAGGGTATCTTCCTGTCTTCCATGTGCCCCATCAATGT CAGCGCCAGCACCTTGTATGGAATTATGTTTGATGCAGGGAGCACTGGAACTCGAATTCATGTT TACACCTTTGTGCAGAAAATGCCAGGACAGCTTCCAATTCTAGAAGGGGAAGTTTTTGATTCTG TGAAGCCAGGACTTTCTGCTTTTGTAGATCAACCTAAGCAGGGTGCTGAGACCGTTCAAGGGCT CTTAGAGGTGGCCAAAGACTCAATCCCCCGAAGTCACTGGAAAAAGACCCCAGTGGTCCTAAAG GCAACAGCAGGACTACGCTTACTGCCAGAACACAAAGCCAAGGCTCTGCTCTTTGAGGTAAAGG AGATCTTCAGGAAGTCACCTTTCCTGGTACCAAAGGGCAGTGTTAGCATCATGACTGGACAAGA $\overline{\texttt{GAGACTGTGGGGGACCTTGGACCTAGGGGGGGGGCCTCCACCCAAATCACGTTCCTGCCCCAGTTTG}$ AGAAAACTCTGGAACAAACTCCTAGGGGCTACCTCACTTCCTTTGAGATGTTTAACAGCACTTA TAAGCTCTATACACATAGTTACCTGGGATTTGGATTGAAAGCTGCAAGACTAGCAACCCTGGGA GCCCTGGAGACAGAAGGGACTGATGGGCACACTTTCCGGAGTGCCTGTTTACCGAGATGGTTGG AAGCAGAGTGGATCTTTGGGGGTGTGAAATACCAGTATGGTGGCAACCAAGAAGGGGAGGTGGG GTCCAGAGAGGTTCCTTCTATGCTTTCTCTTACTATTATGACCGAGCTGTTGACACAGACATGA TTGATTATGAAAAGGGGGGTATTTTAAAAGTTGAAGATTTTGAAAGAAAAGCCAGGGAAGTGTG TGATAACTTGGAAAACTTCACC TCAGGCAGTCCTTTCCTGTGCATGGATCTCAGCTACATCAC GAAC AACATAG AGACGGGCTGGGCCTTGGGGGCCACCTTTCACCTGTTGCAGTCTCTGGGCA TCTCCCATTGA

Amino acid sequence of CD39-L4 mutant ACR III (SEQ ID NO:7). The amino acid changes are D to T (a.a. 168), S to Q (a.a. 170) and L to F (a.a. 175). The changes are shown in bold.

MATSYGTVFFMLVVSCVCSAVSHRNQQTWFEGIFLSSMCPINVSASTLYGIMFDAGSTGT RIHVYTFVQKMPGQLPILEGEVFDSVKPGLSAFVDQPKQGAETVQGLLEVAKDSIPRSHW KKTPVVLKATAGLRLLPEHKAKALLFEVKEIFRKSPFLVPKGSVSIMTGQDEGIFAWVTV NFLTGQLHGHRQETVGTLDLGGASTQITFLPQFEKTLEQTPRGYLTSFEMFNSTYKLYTH SYLGFGLKAARLATLGALETEGTDGHTFRSACLPRWLEAEWIFGGVKYQYGGNQEGEVGF EPCYAEVLRVVRGKLHQPEEVQRGSFYAFSYYYDRAVDTDMIDYEKGGILKVEDFERKAR EVCDNLENFTSGSPFLCMDLSYITALLKDGFGFADSTVLQLTKKVNNIETGWALGATFHL LQSLGISH



MATSWG 1 VFFMLVVSCVCSAVSHRNQQTWFEGIFLSSMCPINVSAS MATSWGT VFFMLVVSCVCSAVSHRNQQTWFEGIFLSSMCPINVSAS MEDTKESNVKTFCSKNILAILGFSSIIAVIA LLAVGLTQ NKALPEN TLYGIMFDAGSTGTRIHVYTFVQKMPGQLPILEGEVFDSVK - PGLSAFVDQPKQG	A ETV Q G L L EV A K D S I P R S H W K K T P V V L K A T A G L R L L P E H K A K A L L F E V K E I F A ETV Q G L L EV A K D S I P R S H W K K T P V V L K A T A G L R L L P E H K A K A L L F E V K E I F G I Y L T D C M E R A R E V I P R S Q H Q E I P D Y L G A T A G M R L L R M F S F F I A C P L L F E V K E I F	RKSPFL"PKGSVSIMDGSDEGILAWVTVNFLTGQLHGHRQRKSPFLVPKGSVSIMDGSDEGILAWVTVNFLTGQL	GTLDLGGASTQITFLPQFEKTLEQTPRGYLTSFEMFNSTYKLYTHSYLGFGLKAA GTLDLGGASTQITFLPQFEKTLEQTPRGYLTSFEMFNSTYKLYTHSYLGFGLKAA SGALDLGGASTQVTFVPQ-NQTIESPDNALQFRLYGKDYNVXTHSFLJCYGKDON	RLATLGALETEG	Y Q Y G G N Q E G E V G F E P C Y A E V L R V V R G K L H Q P E E V Q R G S F Y A F S Y Q Y G G N Q E G E V G F E P C Y A E V L R V V R G K L H Q P E E V Q R G S F Y A F S E I Q G I G N Y Q Q C H Q S I L E L F N T S Y C P Y S Q C A F N G I F L P P L Q G D F G A F S A F S E I Q G I G N Y Q Q C H Q S I L E L F N T S Y C P Y S Q C A F N G I F L P P L Q G D F G A F S A F S E I Q G I G N Y Q Q C H Q S I L E L F N T S Y C P Y S Q C A F N G I F L P P L Q G D F G A F S A F S	D No-3 YYYDR AVDTDMIDYEKGGILKVEDFERKAREVCDNLENFTSGSP-FL CM 378 D No-5 YYYDR AVDTDMIDYEKGGILKVEDFERKAREVCDNLENFTSGSP-FL CM 378 9thman.seq -YFVMKFLNLTSEKVSQEKVTEM-MKKFCAQPWE - EIKTSYAGVKEKYLSEYCF 414	DLSYITALLKDGFGFADST	ALGATFHLLOSLGISH VLR. 89NMIPAEQPLSTPLSHSTYVFLMVLFSLVLFTVAIIGLLIFHRP
SEQ ID No-3 SEQ ID No-5 CD39Human.s SEQ ID No-3 SEQ ID No-5	SEQ ID No-3	SEQ ID No-3	SEQ ID No-3	SEQ ID No-3	SEQ ID No-3	SEQ ID No-3	SEQ ID No-3	· SEQ ID No-3
	SEQ ID No-5	SEQ ID No-5	SEQ ID No-5	SEQ ID No-5	SEQ ID No-5	SEQ ID No-5	SEQ ID No-5	SEQ ID No-5
	CD39Human.se	CD39Human.s	CD39Human .se	CD39Human.seq	CD39Human.seq	CD39Human.seq	CD39Human.seq	CD39Human.seq

MATSWGA -MLIIACVGSTVFYREQQTWFEGVFLSSMCPINV GTFYGIMFDAMATSWG1 FFMLVVSCVCSAVSHRNQQTWFEGIFLSSMCPINV STLYGIMFDAMATSWGTVFFMLVVSCVCSAVSHRNQQTWFEGIFLSSMCPINV SASTLYGIMFDAGSTGTRIHVYTFVQKTAGQLPFLEGEIFDSVKPGLSAFVDQPKQGAETVQELLEV	MPGOLPILEGEVFDSVKPGLS VLKATAGLRLLPEQKAQALLL VLKATAGLRLLPEHKAKALLF VLKATAGLRLLPEHKAKALLF	EGILAWVTVNFLTGQLHGRGQETV EGILAWVTVNFLTGQLHGHRQETV EGILAWVTVNFLTGQLHGHRQETV	AGYLTSFEMFNSTYKLYTHSYLGFGLKAARLATLGALETEGTDGHTFRSACLPR AGYLTSFEMFNSTYKLYTHSYLGFGLKAARLATLGALETEGTDGHTFRSACLPR SCYLTSFEMFNSTYKLYTHSYLGFGLKAARLATLGALETEGTDGHTFRSACLPR EAEWIFGGVKYQYGGNQEGEMGFEPCYAEVLRVVQGKLHOPEEVRGSAFYAFG	LEAEWIFGGVKYQYGGNQEGEVGFEPCYAEVLRVVRGKLHQPEEVQRGSFYAFS VEAEWIFGGVKYQYGGNOEGEVGFEPCYAEVLRVVRGKLHQPEEVQRGSFYAFS YYDRAADTHLIDYEKGGVLKVEDFERKAREVCDNLGSFSSGSPFLCMDLTYITA	VDTDMIDYEKGGILKVEDFERKAREVCDNLENFISGGFAERFAREVCDNLENFTSGGFAERFABENCONLENFTSGGFAERFABENCONLENFYSGHGFADSTVLQLTKKVNNIETGW-ALGATF	
ntpase D No-3 ntpase D No-3	ntpase ID No-3 ID No-5	SEQ ID No-3 I M D G S D SEQ ID No-5 I M D G S D SEQ ID No-5 I M D G S D mur ntpase P R G Y I. T	m :0 ~	ID No-3	SEQ ID No-5 Y Y Y D R A Y SEQ ID No-3 L L K D G L G SEQ ID No-3 L L K D G F G SEQ ID No-5 L L K D G F G	mur ntpase SEPVFS (SEQ ID No-3 SEQ ID No-5